PRX002: Phase I started

Prothena began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate multiple ascending doses of IV PRX002 in up to 60 PD patients. Prothena and Roche partnered last December to co-develop and co-commercialize mAbs targeting SNCA, including PRX002 (see BioCentury, Dec. 16, 2013). ...